Advertisement

Dementias

  • Thomas J. GrabowskiJr.
  • Antonio R. Damasio

Abstract

Approximately 2 million people in the United States suffer from severe dementia, and an additional 5 million have mild to moderate dementia. As life expectancy and the proportion of older individuals in the population continue to increase, dementia will become an ever more significant health problem, one that is compounded by its effects on the families of affected individuals. If the course of dementia is not modified by treatment, the number of individuals who will be affected by degenerative dementia in the coming decades will increase dramatically [1,2].

Keywords

Dementia With Lewy Body Vascular Dementia Cerebral Amyloid Angiopathy Frontotemporal Dementia Clinical Dementia Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schoenberg BS: Epidemiology of Alzheimer’s disease and other dementing illnesses. J Chronic Dis 1986, 39: 1095–1104.PubMedCrossRefGoogle Scholar
  2. 2.
    Hagnell O, Ojesjo L, Rorsman B: Incidence of dementia in the Lundby study. Neuroepidemiology 1992, 11: 61–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  4. 4.
    The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.Google Scholar
  5. 5.
    Hughes CP, Berg L, Danziger WL, et al.: A new clinical scale for the staging of dementia. Brit J Psychiatry 1982,140:566–572.Google Scholar
  6. 6.
    Corey-Bloom J, Thal LJ, Galasko D, et al.: Diagnosis and evaluation of dementia. Neurology 1995, 45:211–218.Google Scholar
  7. 7.
    Practice parameter for diagnosis and evaluation of dementia (summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994, 44:2203–2206.Google Scholar
  8. 8.
    Tombaugh TN, McIntyre NJ: The mini-mental state examination: a comprehensive review. JAGS 1992, 40: 922–935.Google Scholar
  9. 9.
    Folstein MF, Folstein SE, McHugh PR: “Mini-mental ctate.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12: 189–198.PubMedCrossRefGoogle Scholar
  10. 10.
    Petersen RC, Smith GE, Waring SC, et al.: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303–308.Google Scholar
  11. 11.
    Marsden CD: Assessment of dementia. In Handbook of Clinical Neurology. vol 46. Edited by Frederiks JAM. Amsterdam: Elsevier Science Publishers; 1985: 221–231.Google Scholar
  12. 12.
    Albert ML, Feldman RG, Willis AL: The `subcortical dementia’ of progressive supranuclear palsy. J Neurol Neurosurg Psych 1974, 37: 121–130.CrossRefGoogle Scholar
  13. 13.
    Cummings JL, Benson DF: Subcortical dementia. Arch Neurol 1984, 41: 874–879.PubMedCrossRefGoogle Scholar
  14. 14.
    Larrabee GJ, McEntee WJ: Age-associated memory impairment: sorting out the controversies. Neurology 1995, 45: 611–614.PubMedCrossRefGoogle Scholar
  15. 15.
    Koivisto K, Reinikainen KJ, Hanninen MA, et al.: Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. Neurology 1995, 45:741–747.Google Scholar
  16. 16.
    Kaye J, Quinn J: Clinical changes associated with normal aging. In Neurodegenerative Dementias. Edited by Clark CM, Trojanowski JQ New York: McGraw-Hill; 2000.Google Scholar
  17. 17.
    Richards M, Stern Y, Mayeux R: Subtle extrapyramidal signs can predict the development of dementia in elderly individuals. Neurology 1993, 43: 2184–2188.PubMedCrossRefGoogle Scholar
  18. 18.
    Chui HC, Lyness SA, Sobel E, Schneider LS: Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol 1994, 51: 676–681.PubMedCrossRefGoogle Scholar
  19. 19.
    Petersen RC, Smith GE, Ivnik RJ, et al.: Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 1995, 273:1274–1278.Google Scholar
  20. 20.
    Daly E, Zaitchik D, Copeland M, et al.: Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neural 2000, 57:675–680.Google Scholar
  21. 21.
    Jack CR Jr, Petersen RC, Xu YC, et al.: Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997, 49(3):786–794.Google Scholar
  22. 22.
    Killiany RJ, Gomez-Isla T, Moss M, et al.: Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann Neurol 2000, 47:430–439.Google Scholar
  23. 23.
    Albert MS: Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci USA 1996, 93: 13547–13551.PubMedCrossRefGoogle Scholar
  24. 24.
    Fox NC, Warrington EK, Seiffer AL, et al.: Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer’s disease. A longitudinal prospective study. Brain 1998, 121:1631–1639.Google Scholar
  25. 25.
    van Duijn CM: Epidemiology of the dementias: recent developments and new approaches. J Neurol Neurosurg Psych 1996, 60: 478–488.CrossRefGoogle Scholar
  26. 26.
    Brayne C, Gill C, Huppert FA, et al.: Incidence of clinically diagnosed subtypes of dementia in an elderly population. Br J Psychiatr 1995, 167:255–262.Google Scholar
  27. 27.
    Perry E, McKeith I, Perry R, eds.: Dementia with Lewy Bodies: Clinical, Pathologic, and Treatment Issues. Cambridge: Cambridge University Press; 1996.Google Scholar
  28. 28.
    Kertesz A, Munoz D: Pick’s disease, frontotemporal dementia, and Pick complex: emerging concepts. Arch Neurol 1998, 55 (3): 302–304.PubMedCrossRefGoogle Scholar
  29. 29.
    Weytingh MD, Bossuyt PMM, van Crevel H: Reversible dementia: more than 10% or less than 1%? A quantitative review. J Neurol 1995, 242: 446–471.CrossRefGoogle Scholar
  30. 30.
    Mahler ME, Cummings JL, Benson DF: Treatable dementias. West J Med 1987, 146: 705–712.PubMedGoogle Scholar
  31. 31.
    Caine ED: Pseudodementia: current concepts and future directions. Arch Gen Psychiatry 1981, 38: 1359–1364.PubMedCrossRefGoogle Scholar
  32. 32.
    Nussbaum PD: Pseudodementia: a slow death. Neuropsychol Rev 1994; 4 (2): 71–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Abramowicz M: Drugs that cause psychiatric symptoms. Medical Letter 1993, 30: 65–70.Google Scholar
  34. 34.
    Alexander EM, Wagner EH, Buchner DM, et al.: Do surgical brain lesions present as isolated dementia? A population-based study. J Am Geriatr Soc 1995, 43:138–143.Google Scholar
  35. 35.
    Clarfield AM: The reversible dementias: do they reverse? Ann Intern Med 1988, 109: 476–486.PubMedCrossRefGoogle Scholar
  36. 36.
    Sunderland T, Tariot PN, Cohen RM, et al.: Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987, 44:418–426.Google Scholar
  37. 37.
    Blazer DG, Federspiel CF, Ray WA, Schaffner W: The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontology 1983, 38: 31–35.CrossRefGoogle Scholar
  38. 38.
    Cantu TG, Korek JS: Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991, 114: 1027–1034.PubMedCrossRefGoogle Scholar
  39. 39.
    Tiraboschi P, Hansen LA, Alford M, et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407–411.Google Scholar
  40. 40.
    Adams RD, Fisher CM, Hakim S, et al.: Symptomatic occult hydrocephalus with “normal” cerebrospinal-fluid pressure. N Engl J Med 1965, 273:117–126.Google Scholar
  41. 41.
    Fisher CM: Hydrocephalus as a cause of disturbances of gait in the elderly. Neurology 1982, 32: 1358–1363.PubMedCrossRefGoogle Scholar
  42. 42.
    Wikkelso C, Andersson H, Blomstrand C, et al.: Normal pressure hydrocephalus: predictive value of the cerebrospinal fluid tap-test. Acta Neurol Scand 1986, 73:566–573.Google Scholar
  43. 43.
    Graff-Radford NR, Godersky JC, Jones MP: Variables predicting surgical outcome in symptomatic hydrocephalus in the elderly. Neurology 1989, 39: 1601–1604.PubMedCrossRefGoogle Scholar
  44. 44.
    Benton AL: Neuropsychological assessment. Annu Rev Psychol 1994, 45: 1–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Jones RD, Tranel D, Benton A, Paulsen J: Differentiating dementia from “pseudodementia” early in the clinical course: utility of neuropsychological tests. Neuropsychology 1992, 6: 13–21.CrossRefGoogle Scholar
  46. 46.
    Harner RN: EEG evaluation of the patient with dementia. In Psychiatric Aspects of Neurologic Disease. Edited by Benson DF, Blumer D. New York: Grune & Stratton; 1975: 63–82.Google Scholar
  47. 47.
    Caselli RJ, Jack CR, Petersen RC, et al.: Asymmetric cortical degenerative syndromes: clinical and radiologic correlations. Neurology 1992, 42:1462–1468.Google Scholar
  48. 48.
    Duara R, Grady C, Haxby J, et al.: Positron emission tomography in Alzheimer’s disease. Neurology 1986, 36:879–887.Google Scholar
  49. 49.
    Powers WJ, Perlmutter JS, Videen TO, et al.: Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease. Neurology 1992, 42:765–770.Google Scholar
  50. 50.
    Alzheimer A: On a peculiar disease of the cerebral cortex. Allgemeine Zeitschrift 1907, 64: 146–148.Google Scholar
  51. 51.
    Khachaturian ZS: Diagnosis of Alzheimer’s disease. Arch Neurol 1985, 42: 1097–1105.PubMedCrossRefGoogle Scholar
  52. 52.
    Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s disease. Neurobiol Aging 1997, 18: S1 - S2.Google Scholar
  53. 53.
    Mirra SS, Heyman A, McKeel D, et al.: The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991, 41:479–486.Google Scholar
  54. 54.
    Gearing M, Mirra SS, Hedreen JC, et al.: The consortium to establish a registry for Alzheimer’s disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology 1995, 45:461–466.Google Scholar
  55. 55.
    McKhann G, Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984, 34:939–944.Google Scholar
  56. 56.
    Katzman R, Kawas C: The epidemiology of dementia and Alzheimer disease. In Alzheimer Disease. Edited by Terry RD, Katzman R, Bick KL. New York: Raven Press; 1994: 105–122.Google Scholar
  57. 57.
    Jorm AF, Korten E, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987, 76: 465–479.PubMedCrossRefGoogle Scholar
  58. 58.
    van Duijn CM, Stijnen T, Hofman A: Risk factors for Alzheimer’s disease: overview of the EURODEM collaborative re-analysis of case-control studies. Int J Epidemiol 1991, 20: S4 - S12.PubMedCrossRefGoogle Scholar
  59. 59.
    Goate A, Chartier-Harlin MC, Mullan M, et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991, 349:704–706.Google Scholar
  60. 60.
    Levy-Lahad E, Wasco W, Poorkaj P, et al.: Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995, 269:(5226)973–977.Google Scholar
  61. 61.
    Alzheimer’s Disease Collaborative Group: The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 1995, 11:(2)219–222.Google Scholar
  62. 62.
    Cummings JL, Vinters HV, Cole GM, Khachaturian ZS: Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51 (1 Suppl 1): S2–17.PubMedCrossRefGoogle Scholar
  63. 63.
    Tang M-X, Jacobs D, Stern Y, et al.: Effect of estrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996, 348:429–432.Google Scholar
  64. 64.
    Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995, 92: 4725–4727.PubMedCrossRefGoogle Scholar
  65. 65.
    Myers RH, Schaefer EJ, Wilson PWF, et al.: Apolipoprotein E4 association with dementia in a population-based study: The Framingham Study. Neurology 1996, 46:673–677.Google Scholar
  66. 66.
    Welsh-Bohmer KA, Gearing M, Saunders ANI, et al.: Apolipoprotein E genotypes in a neuropathological series from the consortium to establish a registry for Alzheimer’s disease. Ann Neurol 1997, 42:319–325.Google Scholar
  67. 67.
    Breitner JCS: The end of Alzheimer’s disease? Intl Geriatr Psychiatry 1999, 14: 577–586.CrossRefGoogle Scholar
  68. 68.
    Hyman BT, Gomez-Isla T, Briggs M, et al.: Apolipoprotein E and cognitive change in an elderly populations. Ann Neurology 1996, 40:55–66.Google Scholar
  69. 69.
    Mayeux R, Saunders AlVI, Shea S, et al.: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med 1998, 338:506–511.Google Scholar
  70. 70.
    Strittmatter WJ, Saunders AM, Schmechel D, et al.: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977–1981.Google Scholar
  71. 71.
    Pickering-Brown SM, Mann DMA, Bourke JP, et al.: Apolipoprotein E4 and Alzheimer’s disease pathology in Lewy body disease and in other beta-amyloid-forming diseases. Lancet 1994, 343:11–55.Google Scholar
  72. 72.
    Ellis RJ, Olichney JM, Thal LJ, et al.: Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, part XV. Neurology 1996, 46:1592–1596.Google Scholar
  73. 73.
    Storey E, Cappai R: The amyloid precursor protein of Alzheimer’s disease and the Aß peptide. Neuropathol Appl Neurobiol 1999, 25: 81–97.PubMedCrossRefGoogle Scholar
  74. 74.
    Selkoe DJ: Alzheimer’s disease: a central role for amyloid. J Neuropathol Exp Neurol 1994, 53: 438–447.PubMedCrossRefGoogle Scholar
  75. 75.
    Selkoe DJ: The pathophysiology of Alzheimer’s disease. In Early Diagnosis of Alzheimer’s Disease. Edited by Scinto LFM, Daffner KR. Totowa, NJ: Humana Press; 2000: 83–104CrossRefGoogle Scholar
  76. 76.
    Arnold SE, Hyman BT, Flory J, et al.: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex 1991, 1:103–116.Google Scholar
  77. 77.
    Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica 1991, 82: 239–259.PubMedCrossRefGoogle Scholar
  78. 78.
    Hyman BT, Arriagada PV, McKee AC, et al.: The earliest symptoms of Alzheimer disease: anatomic correlates. Soc Neurosci Abstr 1991,15:352.Google Scholar
  79. 79.
    Hof PR, Bierer LM, Perl DP, et al.: Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Arch Neural 1992, 49:946–953.Google Scholar
  80. 80.
    Scinto LFM, Daffner KR: Early Diagnosis of Alzheimer’s Disease. Totowa, NJ: Humana Press; 2000.CrossRefGoogle Scholar
  81. 81.
    Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976, 1403.Google Scholar
  82. 82.
    Bartus RT, Dean RLI, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–414.PubMedCrossRefGoogle Scholar
  83. 83.
    Coyle JT, Price DL, DeLong MR: Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 1983, 219: 1184–1190.PubMedCrossRefGoogle Scholar
  84. 84.
    Knapp MJ, Knopman DS, Solomon PR, et al.: A 30-week randomized controlled trial of high-dose tracrine in patients with Alzheimer’s disease. JAMA 1994, 271:985–991.Google Scholar
  85. 85.
    Mayeux R, Sano M: Treatment of Alzheimer’s disease. N Engl J Med 1999, 341: 1670–1679.PubMedCrossRefGoogle Scholar
  86. 86.
    Geula C, Mesulam MM: Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer’s disease. Cerebral Cortex 1996, 6: 165–177.PubMedCrossRefGoogle Scholar
  87. 87.
    Hyman BT, Van Hoesen G, Damasio AR, Barnes CL: Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225: 1168–1170.PubMedCrossRefGoogle Scholar
  88. 88.
    Reiman EM, Caselli RJ, Yun LS, et al.: Preclinical evidence of Alzheimer’s disease in persons homozygous for the (epsilon) 4 allele for apolipoprotein E. N Engl J Med 1996, 334:752–758.Google Scholar
  89. 89.
    Hof PR, Bouras C, Constantinidis J, Morrison JH: Selective disconnection of specific visual association pathways in cases of Alzheimer’s disease presenting with Balint’s syndrome. J Neuropathol Exp Neural 1990, 40: 168–184.CrossRefGoogle Scholar
  90. 90.
    Levine DN, Lee JM, Fisher CM: The visual variant of Alzheimer’s disease. Neurology 1993, 43: 305–313.PubMedCrossRefGoogle Scholar
  91. 91.
    Victoroff J, Webster R, Benson F, et al.: Posterior cortical atrophy. Neuropathologic correlations. Arch Neurol 1994, 51:269–274.Google Scholar
  92. 92.
    Joaquim CL, Morris JH, Selkoe DJ: Clinically diagnosed Alzheimer’s disease: autopsy results in 150 cases. Ann Neurol 1988, 24: 50–56.CrossRefGoogle Scholar
  93. 93.
    Wade JPH, Mirsen TR, Hachinski VC, et al.: The clinical diagnosis of Alzheimer’s disease. Arch Neural 1987, 44:24–29.Google Scholar
  94. 94.
    Molsa PK, Paljarvi L, Rinne JO, et al.: Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J Neurol Neurosurg Psychiatr 1985,48:1085–1090.Google Scholar
  95. 95.
    Klatka LA, Schiffer RB, Powers JM, Kazee AM: Incorrect diagnosis of Alzheimer’s disease: a clinicopathologic study. Arch Neurol 1996, 53: 35–42.PubMedCrossRefGoogle Scholar
  96. 96.
    Dickson DW, Davies P, Bevona C, et al.: Hippocampal sclerosis: a common pathological feature of dementia in very old (over 80 years of age) humans. Acta Neuropathol 1994, 88:212–221.Google Scholar
  97. 97.
    Ala TA, Beh GO, Frey II WH: Pure hippocampal sclerosis. Neurology 2000, 54: 843–848.PubMedCrossRefGoogle Scholar
  98. 98.
    Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. NeurobiolAging 1998, 19: 109–116.Google Scholar
  99. 99.
    Galasko D, Clark C, Chang L, et al.: Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 1997, 48:632–635.Google Scholar
  100. 100.
    Kahle PJ, Jakowec M, Teipel SJ, et al.: Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology 2000, 54:1498–1504.Google Scholar
  101. 101.
    Roman GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43: 250–260.PubMedCrossRefGoogle Scholar
  102. 102.
    Tatemichi TK: How acute brain failure becomes chronic: a view of the mechanisms of dementia related to stroke. Neurology 1990, 40: 1652–1659.PubMedCrossRefGoogle Scholar
  103. 103.
    Tatemichi TK, Desmond DW, Paik M, et al.: Clinical determinants of dementia related to stroke. Ann Neurol 1993, 33:568–575.Google Scholar
  104. 104.
    Erkinjuntti T, Hachinski VC: Rethinking vascular dementia. Cerebrovasc Dis 1993, 3: 3–23.CrossRefGoogle Scholar
  105. 105.
    Chui HC, Victoroff JI, Margolin D, et al.: Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer’s disease diagnostic and treatment centers. Neurology 1992, 42:473–480.Google Scholar
  106. 106.
    Rockwood K, Parhad I, Hachinski V, et al.: Diagnosis of vascular dementia: consortium of Canadian Centres for clinical cognitive research consensus statement. Can J Neurol Sci 1994, 21:358–364. 132.Google Scholar
  107. 107.
    Verhey FRJ, Lodder J, Rozendaal N, Jolles J: Comparison of seven sets of criteria used for the diagnosis of vascular dementia. Neuroepidemiology 1996, 15: 166–172.PubMedCrossRefGoogle Scholar
  108. 108.
    Erkinjuntti T, Haltia M, Palo J, et al.: Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study. J Neurol Neurosurg Psychiatr 1988, 51:1037–1044.Google Scholar
  109. 109.
    Gold G, Giannakpoulos P, Montes-Paixao C, et al.: Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997, 49:690–694.Google Scholar
  110. 110.
    Tatemichi TK, Desmond DW, Mayeux R, et al.: Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992,42:1185–1193.Google Scholar
  111. 111.
    Hebert R, Brayne C: Epidemiology of vascular dementia. Neuroepidemiology 1995, 14: 240–257.PubMedCrossRefGoogle Scholar
  112. 112.
    Hachinski V, Lassen NA, Marshall J: Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet 1974, 1: 207–210.CrossRefGoogle Scholar
  113. 113.
    Hachinski VC, et al: Cerebral blood flow in dementia. Arch Neurol 1975, 32: 632–637.PubMedCrossRefGoogle Scholar
  114. 114.
    Rosen WG, Terry RD, Fuld PA, et al.: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980, 7: 486–488.PubMedCrossRefGoogle Scholar
  115. 115.
    Fischer P, Jellinger K, Gatterbi G, Danielczyk W: Prospective neuropathological validation of Hachinski’s ischaemic score in dementias. J Neurol Neurosurg Psychiatr 1991, 54: 580–583.PubMedCrossRefGoogle Scholar
  116. 116.
    Hershey LA, Modic MT, Jaffe DF, Greenough PG: Natural history of the vascular dementias: a prospective study of seven cases. Can J Neurol Sci 1986, 13: 559–565.PubMedGoogle Scholar
  117. 117.
    Snowdon DA, Greiner LH, Mortimer JA, et al.: Brain infarction and the clinical expression of Alzheimer disease. The Nun study. JAMA 1997, 277:813–817.Google Scholar
  118. 118.
    Esiri MM, Nagy Z, Smith MZ, et al.: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999, 354:919–920.Google Scholar
  119. 119.
    Lie JT: Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol 1992, 23: 164–171.PubMedCrossRefGoogle Scholar
  120. 120.
    Caplan LR: Binswanger’s disease-revisited. Neurology 1995, 45: 626–633.PubMedCrossRefGoogle Scholar
  121. 121.
    Fisher CM: Binswanger’s encephalopathy: a review. J Neurol 1989, 236: 65–79.PubMedCrossRefGoogle Scholar
  122. 122.
    Greenberg SM, Finklestein SP, Schaefer PW: Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996, 46: 1751–1754.PubMedCrossRefGoogle Scholar
  123. 123.
    Greenberg SM, Vonsattel JPG, Stakes JW, et al.: The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993, 43:2073–2079.Google Scholar
  124. 124.
    Hutchinson, M, O’Riordan J, Javed M, et al.: Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol 1995, 38:817–824.Google Scholar
  125. 125.
    Dichgans M, Mayer M, Uttner I, et al.: The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998, 44:731–739.Google Scholar
  126. 126.
    The Lund and Manchester Groups: Clinical and neuropathological criteria for frontotemporal dementia. J Neuro Neurosurg Psychiatry 1994, 57: 416–418.Google Scholar
  127. 127.
    Neary D, Snowden JS, Gustafson L, et al.: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546–1554.Google Scholar
  128. 128.
    Brun A: Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr 1987, 6: 193–208.PubMedCrossRefGoogle Scholar
  129. 129.
    Neary D, Snowden JS, Mann DMA, et al.: Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990, 53:23–32.Google Scholar
  130. 130.
    Chow TW, Miller BL, Hayashi VN, Geschwind DH: Inheritance of frontotemporal dementia. Arch Neurol 1999, 56 (7): 817–822.PubMedCrossRefGoogle Scholar
  131. 131.
    Tissot R, Constantinidis J, Richard J: Pick’s Disease. In Handbook of Clinical Neurology vol 46. Edited by Frederiks JAM. Amsterdam: Elsevier Science Publishers; 1985: 233–246.Google Scholar
  132. 132.
    Mesulam MM: Slowly progressive aphasia without generalized dementia. Ann Neurol 1982, 11: 592–598.PubMedCrossRefGoogle Scholar
  133. 133.
    Snowden JS, Neary D, Mann DMA: Fronto-Temporal Lobar Degeneration: Fronto-Temporal Dementia, Progressive Aphasia, Semantic Dementia. New York: Churchill Livingstone; 1996.Google Scholar
  134. 134.
    Kertesz A, Hudson L, Mackenzie IRA, Munoz DG: The pathology and nosology of primary progressive aphasia. Neurology 1994, 44: 2065–2072.PubMedCrossRefGoogle Scholar
  135. 135.
    Turner RS, Kenyon LC, Trojanowski JO,, et al.: Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Ann Neurol 1996, 39:166–173.Google Scholar
  136. 136.
    Knopman DS, Mastri AR, Frey II WH, et al.: Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 1990, 40:251–256.Google Scholar
  137. 137.
    Knopman DS: Overview of dementia lacking distinctive histology: pathological designation of a progréssive dementia. Dementia 1993, 4: 132–136.PubMedGoogle Scholar
  138. 138.
    Giannakopoulos P, Hof PR, Bouras C: Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol 1995, 89: 346–355.PubMedCrossRefGoogle Scholar
  139. 139.
    Graff-Radford NR, Damasio AR, Hyman BT, et al.: Progressive aphasia in a patient with Pick’s disease: a neuropsychological, radiologic, and anatomicstudy. Neurology 1990, 40:620–626.Google Scholar
  140. 140.
    Hodges JR, Patterson K, Oxbury S, Funnell E: Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992, 115: 1783–1806.PubMedCrossRefGoogle Scholar
  141. 141.
    Gibb WRG, Luthert PJ, Marsden CD: Corticobasal degeneration. Brain 1989, 112: 1171–1192.PubMedCrossRefGoogle Scholar
  142. 142.
    Boeve BF, Maraganore DM, Parisi JE, et al.: Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999, 53:795–800.Google Scholar
  143. 143.
    Grimes DA, Lang AE, Bergeron CB: Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999, 53: 1969–1974.PubMedCrossRefGoogle Scholar
  144. 144.
    Foster NL, Wilhelmsen K, Sima AAF, et al.: Frontotemporal dementia and Parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 163. 1997, 41:706–715.Google Scholar
  145. 145.
    Spillantini, MG, Bird TD, Ghetti B: Frontotemporal dementia and parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathology 1998, 8: 387–402.PubMedCrossRefGoogle Scholar
  146. 146.
    Spillantini MG, Goedert M: Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998, 21: 428–433.PubMedCrossRefGoogle Scholar
  147. 147.
    Bennet P, Bonifati V, Bonuccelli U, et al.: Direct genetic evidence for involvement of tau in progressive supranuclear palsy. European Study Group on Atypical Parkinsonism Consortium. Neurology 1998, 51:982–985.Google Scholar
  148. 148.
    Gearing M, Olson DA, Watts RL, Mirra SS: Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994, 44: 1015–1024.PubMedCrossRefGoogle Scholar
  149. 149.
    de Vos RA, Jansen EN, Stam FC, Swaab DF: `Lewy body disease’: clinicopathological correlations in 18 consecutive cases of Parkinson’s disease with and without dementia. Clin Neurol Neurosurg 1995, 97: 13–22.PubMedCrossRefGoogle Scholar
  150. 150.
    Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 169. 100 cases of Parkinson’s disease. Arch Neurol 1993, 50: 140–148.PubMedCrossRefGoogle Scholar
  151. 151.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Psychiatry 1992, 55: 181–184.Google Scholar
  152. 152.
    Hulette C, Mirra S, Wilkinson W, et al.: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson’s features in Alzheimer’s disease. Neurology 1996, 45:1991–1995.Google Scholar
  153. 153.
    Ditter SM, Mirra SS: Neuropathologic and clinical features of Parkinson’s disease in Alzheimer’s disease patients. Neurology 1987, 37: 754–760.PubMedCrossRefGoogle Scholar
  154. 154.
    Dickson DW, Ruan D, Crystal H, et al.: Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2–3 neurites specific to DLBD. Neurology 1991, 41:1402–1409.Google Scholar
  155. 155.
    Kim H, Gearing M, Mirra SS: Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology 1995, 45: 1768–1770.PubMedCrossRefGoogle Scholar
  156. 156.
    Lippa CF, Johnson R, Smith TW: The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer’s disease. Ann Neurol 1998, 43: 102–106.PubMedCrossRefGoogle Scholar
  157. 157.
    McKeith IG, Fairbairn AF, Bothwell RA, et al.: An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994, 44:872–877.Google Scholar
  158. 158.
    McKeith IG, Ballard CG, Perry RH, et al.: Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000, 54:1050–1058.Google Scholar
  159. 159.
    Verghese J, Crystal HA, Dickson DW, Lipton RB: Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999, 53: 1974–1982.PubMedCrossRefGoogle Scholar
  160. 160.
    McKeith IG, Perry EK, Perry RH: Report of the second dementia with Lewy body international workshop. Neurology 1999, 53: 902–905.PubMedCrossRefGoogle Scholar
  161. 161.
    Boeve BF, Silber MH, Ferman TJ, et al.: REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998, 51:363–370.Google Scholar
  162. 162.
    McKeith I, Fairbairn A, Perry R, et al.: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992, 305:673–678.Google Scholar
  163. 163.
    Ballard C, Grace J, McKeith I, Holmes C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998, 351: 1032–1033.PubMedCrossRefGoogle Scholar
  164. 164.
    Walker MP, Ayre GA, Cummings JL, et al.: Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology 2000, 54:1616–1624.Google Scholar
  165. 165.
    Prusiner SB: The prion diseases. Sci Am 1995, 272: 48–57.PubMedCrossRefGoogle Scholar
  166. 166.
    Bortone E, Bettoni L, Giorgi C, et al.: Reliability of EEG in the diagnosis of Creutzfeldt-Jakob disease. Electroencephalogr Clin Neurophysiol 1994, 90:323–330.Google Scholar
  167. 167.
    Steinhoff BJ, Racker S, Herrendorf G, et al.: Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996, 53:162–166.Google Scholar
  168. 168.
    Zerr I, Bodemer M, Gefeller O, et al.: Detection of 14–3–3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt–Jakob disease. Ann Neurol 1998, 43:32–40.Google Scholar
  169. 169.
    Na DL, Suh CK, Choi SH, et al.: Diffusion-weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomic correlation. Arch Neurol 1999, 56(8):951–957.Google Scholar
  170. 170.
    DeArmond SJ, Prusiner SB: Etiology and pathogenesis of prion diseases. Am J Pathol 1995, 146: 785–811.PubMedGoogle Scholar
  171. 171.
    Parchi P, Giese A, Capellari S, et al.: Classification of sporadic CreutzfeldtJakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999 46:224–233.Google Scholar
  172. 172.
    Mestel R: Putting prions to the test. Science 1996, 273: 184–189.PubMedCrossRefGoogle Scholar
  173. 173.
    Will RG, Ironside JW, Zeidlee M, et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347:921–925.Google Scholar
  174. 174.
    Johnson RT, Gibbs CJ: Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998, 339: 1994–2004.PubMedCrossRefGoogle Scholar
  175. 175.
    Gultekin SH, Rosenfeld MR, Voltz R, et al.: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000, 123:1481–1494.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Thomas J. GrabowskiJr.
  • Antonio R. Damasio

There are no affiliations available

Personalised recommendations